- Home
- FITBO vs SCLXW Comparison
FITBO vs SCLXW Comparison
Compare FITBO & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
FITBO
Fifth Third Bancorp Depositary Shares each representing a 1/1000th ownership interest in a share of Non-Cumulative Perpetual Preferred Stock Series K
Current Price
Company Overview
Basic Information| Metric | FITBO | SCLXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 18616 | 30 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FITBO | SCLXW |
|---|---|---|
| Price | $19.65 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 14.9K | 1.8K |
| Earning Date | N/A | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $19.19 | $0.04 |
| 52 Week High | $22.80 | $0.64 |
Technical Indicators
Market Signals| Indicator | FITBO | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 36.00 | 40.25 |
| Support Level | $19.20 | $0.11 |
| Resistance Level | $19.85 | $0.12 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 0.00 | 21.16 |
Price Performance
Historical ComparisonAbout FITBO Fifth Third Bancorp Depositary Shares each representing a 1/1000th ownership interest in a share of Non-Cumulative Perpetual Preferred Stock Series K
Fifth Third Bancorp is a midsize regional bank in the US, with total assets of over $210 billion as of December 2025. The bank is set to close its acquisition of Comercia on Feb. 1, 2026. Headquartered in Cincinnati, Ohio, Fifth Third has a strong presence in the US Midwest and is currently expanding in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and Treasury management, wealth and asset management, and capital markets.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.